{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:17:51Z","timestamp":1760660271514,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":2517,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.rmed.2006.01.025","type":"journal-article","created":{"date-parts":[[2006,3,14]],"date-time":"2006-03-14T09:28:24Z","timestamp":1142328504000},"page":"1781-1790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents"],"prefix":"10.1016","volume":"100","author":[{"given":"M.S.","family":"Niederman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Anzueto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Choudhri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kureishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Haverstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Perroncel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2006.01.025_bib1","first-page":"353","article-title":"The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature review","volume":"9","author":"Halpern","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.rmed.2006.01.025_bib2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0149-2918(00)88310-1","article-title":"Treatment cost of acute exacerbations of chronic bronchitis","volume":"21","author":"Niederman","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.rmed.2006.01.025_bib3","series-title":"Clinical epidemiology of chronic obstructive pulmonary disease","article-title":"Incidence, prevalence and mortality: intra- and inter-country difference","author":"Higgins","year":"1990"},{"key":"10.1016\/j.rmed.2006.01.025_bib4","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1378\/chest.108.2_Supplement.43S","article-title":"Epidemiology and treatment of chronic bronchitis and its exacerbations","volume":"108","author":"Ball","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2006.01.025_bib5","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1164\/ajrccm.152.4.7551388","article-title":"Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush","volume":"152","author":"Monso","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2006.01.025_bib6","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1378\/chest.113.6.1542","article-title":"Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function","volume":"113","author":"Eller","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2006.01.025_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1378\/chest.116.1.40","article-title":"Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD","volume":"116","author":"Miravitlles","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2006.01.025_bib8","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1164\/ajrccm.157.5.9711044","article-title":"Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation","volume":"157","author":"Soler","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2006.01.025_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMoa012561","article-title":"New strains of bacteria and exacerbations of chronic obstructive pulmonary disease","volume":"347","author":"Sethi","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2006.01.025_bib10","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1164\/rccm.200308-1181OC","article-title":"Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease","volume":"169","author":"Sethi","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2006.01.025_bib11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/514934","article-title":"Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group","volume":"27","author":"Chodosh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmed.2006.01.025_bib12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0149-2918(02)85139-6","article-title":"A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes","volume":"24","author":"Wilson","year":"2002","journal-title":"Clin Ther"},{"issue":"Suppl B","key":"10.1016\/j.rmed.2006.01.025_bib13","first-page":"3B","article-title":"Canadian guidelines for the management of acute exacerbations of chronic bronchitis","volume":"10","author":"Balter","year":"2003","journal-title":"Can Respir J"},{"key":"10.1016\/j.rmed.2006.01.025_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0163-4453(03)00123-3","article-title":"Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01","volume":"48","author":"Doern","year":"2004","journal-title":"J Infect"},{"key":"10.1016\/j.rmed.2006.01.025_bib15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0732-8893(03)00089-0","article-title":"Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program","volume":"47","author":"Johnson","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.rmed.2006.01.025_bib16","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1046\/j.1469-0691.2003.00573.x","article-title":"In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000\u20132001","volume":"9","author":"Jones","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmed.2006.01.025_bib17","first-page":"131","article-title":"[Sensitivity of Haemophilus influenzae isolates in Spain to 17 oral antibiotics]","volume":"21","author":"Aracil","year":"2003","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.rmed.2006.01.025_bib18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ijantimicag.2003.09.022","article-title":"Antimicrobial resistance of Streptococcus pneumoniae and Haemophilus influenzae in Sao Paulo, Brazil from 1996 to 2000","volume":"23","author":"Koeth","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.rmed.2006.01.025_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0022-3476(05)80601-8","article-title":"Measuring the comparative efficacy of antibacterial agents for acute otitis media: the \u201cPollyanna phenomenon\u201d","volume":"120","author":"Marchant","year":"1992","journal-title":"J Pediatr"},{"key":"10.1016\/j.rmed.2006.01.025_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.otohns.2003.12.003","article-title":"Antimicrobial treatment guidelines for acute bacterial rhinosinusitis","volume":"130","author":"Anon","year":"2004","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.rmed.2006.01.025_bib21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1378\/chest.125.3.953","article-title":"Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis","volume":"125","author":"Wilson","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2006.01.025_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijantimicag.2003.09.012","article-title":"Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis","volume":"23","author":"Starakis","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.rmed.2006.01.025_bib23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1179\/joc.2002.14.6.597","article-title":"Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB)","volume":"14","author":"Grassi","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.rmed.2006.01.025_bib24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1742-1241.2001.tb11086.x","article-title":"The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience","volume":"55","author":"Miravitlles","year":"2001","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.rmed.2006.01.025_bib25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1053\/rmed.2000.0927","article-title":"The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis","volume":"94","author":"DeAbate","year":"2000","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2006.01.025_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/rmed.1999.0708","article-title":"Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group","volume":"94","author":"Chodosh","year":"2000","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2006.01.025_bib27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/jac\/44.4.501","article-title":"Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis","volume":"44","author":"Wilson","year":"1999","journal-title":"J Antimicrob Chemother"},{"year":"2000","series-title":"Performance standards for antimicrobial disk susceptibility tests; seventh edition: approved standard M2-A7","key":"10.1016\/j.rmed.2006.01.025_bib28"},{"year":"2000","series-title":"Method for dilution antimicrobial susceptibility testing for bacteria that grow aerobically; fifth edition: approved standard M7-A5","key":"10.1016\/j.rmed.2006.01.025_bib29"},{"year":"1997","series-title":"Performance standards for antimicrobial disk susceptibility tests; sixth edition: approved standard M2-A6","key":"10.1016\/j.rmed.2006.01.025_bib30"},{"year":"1997","series-title":"Method for dilution antimicrobial susceptibility testing for bacteria that grow aerobically; fourth edition: approved standard M7-A4","key":"10.1016\/j.rmed.2006.01.025_bib31"},{"key":"10.1016\/j.rmed.2006.01.025_bib32","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Fifteenth Informational Supplement: CLSI Document M100-S15 (ISBN:1-56238-566-9). Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2005."},{"key":"10.1016\/j.rmed.2006.01.025_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jac\/47.2.129","article-title":"Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy","volume":"47","author":"Dagan","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmed.2006.01.025_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/49.1.31","article-title":"Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimised resistance emergence","volume":"49","author":"Ball","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmed.2006.01.025_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid0901.020277","article-title":"Maintaining fluoroquinolone class efficacy: review of influencing factors","volume":"9","author":"Scheld","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.rmed.2006.01.025_bib36","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/archinte.165.8.891","article-title":"Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease","volume":"165","author":"Rosell","year":"2005","journal-title":"Arch Intern Med"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461110600059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461110600059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:22:13Z","timestamp":1760610133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461110600059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S095461110600059X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2006.01.025","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2006,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2006.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}